TABLE 1.
No. | Name | Molecular weight | Main structure | Bioactivity | References |
---|---|---|---|---|---|
1 | LMw-APS | 5.6 × 103 | Backbone composed of (1→4) linked glucose and some (1→2) linked Xyl and (1→3) linked GalA | Immunomodulatory activity | Qu (2010) |
2 | APS | 2 × 104–6 × 104 | (1→4)-α-glucan, arabinogalactan, rhamnose-galacturonic acid glycan, and arabinose-galactose proteoglycan | Immunomodulatory activity | Qing-yang et al. (2017) |
3 | APS | 2.07 × 104 | (1→4)-linked Glc backbone with a (1→6)-linked Glc branch | Antioxidant and immunomodulation | Niu et al. (2011) |
4 | APS | 8.7 × 103–4.8 × 106 | Backbone composed of α-(1→3) glucose and some (1→4), (1→6) glucoses | Antitumor | Zhen-yuan et al. (2011) |
5 | AMon-S | 7.6 × 104 | Mainly α-arabino-β-3,6-galactan-type structural units | Reticuloendothelial system-potentiating activity | Shimizu et al. (1991) |
6 | APS | 1.6 × 106 | Glucose, galactose, mannose, and arabinose | Antioxidant activity | Yan et al. (2010) |
7 | APS | 1.2 × 104–3.6 × 104 | Backbone mainly composed of α-d-(1→4)-linked Glc | Antiatherosclerosis and antidiabetes | Wang et al. (2010) |
8 | cAMPs-1A | 1.23 × 104 | α-glycosidic linkage | Immunomodulation and antitumor | An-Jun et al. (2017) |
9 | A2Nb | 6.99 × 104–1.58 × 105 | Arabinogalactan | Immunomodulation | Wu X. et al. (2011) |
10 | APS4 | 1.23 × 104 | (1→2)-α-d-Glcp and (1→2,6)-α-d-Glcp | Antitumor | Yu et al. (2019) |